Skip to main content

Reata Pharmaceuticals has been acquired by Biogen. Please visit www.biogen.com for more information.

Site Search
Reata Pharmaceuticals Inc. logo
  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations
  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations
  • Twitter opens in a new window
  • Linkedin opens in a new window
  • Facebook opens in a new window
  • Instagram opens in a new window

Partnering & In-Licensing

  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations

We are committed to partnering with leading academic institutions, as well as biotechnology and pharmaceutical companies, to in-license and collaboratively develop promising therapeutics. Our licensing and partnering efforts focus on innovative approaches that target pathophysiological processes driving intractable diseases.

At present, we welcome new opportunities in mitochondrial and inflammatory diseases to complement our internal development programs. Our long-standing involvement in these therapeutic areas positions us to leverage our expertise and drive the development of therapeutics.

At Reata, we independently consider the potential strategic fit for each unique opportunity presented to us. We are looking to expand our portfolio and will consider compounds with the characteristics outlined below:

  • Novel/profound biology
    • New or unknown targets
    • Unique approaches to modulating validated targets
    • First-in-class or best-in-class potential
  • An identified (but not necessarily optimized) lead molecule
  • Small molecules are preferred to biologics
  • Efficacy in animal model(s) of the target disease
  • Potential to be IND-ready within 24 months

If you have a new technology that you believe would fit with our approach or would like to learn more about our in-licensing efforts, please use the Contact Us form or email us at BD@reatapharma.com.

hand shake
Plains in West Texas
Reata Pharmaceuticals Inc. logo

Intended for US residents only.

  • Sitemap
  • Legal Message
  • Privacy Notice
  • Social Media Disclosure
  • Contact Us
Powered By Q4 Inc. 5.104.0.1 (opens in new window)

© Reata Pharmaceuticals, Inc., All Rights Reserved. | US-NON-2100018 | 09/2023

Stay Connected Mobile

  • Twitter opens in a new window
  • Linkedin opens in a new window
  • Facebook opens in a new window
  • Instagram opens in a new window